Platelet function testing and implications for clinical practice.

abstract：BACKGROUND:Myocardial infarction causes the acidification of the cellular environment and the resultant acidosis maybe arrhythmogenic. The effect of acidosis on the action of antiarrhythmic drugs, an important issue in the antiarrhythmic drug therapy after myocardial infarction, remains to be studied. METHODS:To evalu...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lin C,Ke X,Cvetanovic I,Ranade V,Somberg J

更新日期：2005-03-01 00:00:00

abstract：BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Varagic J,Susic D,Slama M,Frohlich ED

更新日期：2003-06-01 00:00:00

abstract：BACKGROUND:We hypothesized that the cardioprotective effect of angiotensin II (AngII) type 1 receptor (AT(1)R) blockade during in vivo ischemia-reperfusion (IR) might be associated with an increase in AngII type 2 receptor (AT(2)R) protein, as well as 1,4,5-inositol trisphosphate type 2 receptor (IP(3)R) and protein ki...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Jugdutt BI,Xu Y,Balghith M,Moudgil R,Menon V

更新日期：2000-10-01 00:00:00

abstract：PURPOSE:It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tosaka S,Tosaka R,Matsumoto S,Maekawa T,Cho S,Sumikawa K

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Whether cardioprotection induced by the angiotensin II (AngII) type 2 receptor (AT(2)R) antagonist PD123,319 (PD) after ischemia-reperfusion (IR) is influenced by the concentration of PD, presence of AngII, timing of exposure, or inhibition of proton production from glucose metabolism is not known. METHODS ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ford WR,Clanachan AS,Jugdutt BI

更新日期：2000-07-01 00:00:00

abstract：:BACKGROUND: Conventional microelectrode techniques were used to compare the concentration-dependent effects of vesnarinone (0.1-100 µM) and amrinone (1 µM-1 mM) on action potential duration (APD) and developed force in both isolated dog ventricular trabeculae and Purkinje strands. METHODS AND RESULTS: Both drugs incre...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lathrop DA,Nánási PP,Varró A,Schwartz A

更新日期：1996-04-01 00:00:00

abstract：:The presenting signs of osteogenic osteosarcoma are commonly pain, local swelling, local warmth, pathologic fracture, and metastatic disease. Deep venous metastasis of osteoblastic osteosarcoma is most often a postmortem diagnosis. This paper describes the case of a previously healthy 18-year-old woman who presented w...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Shah AP,Parmar S,O'Regan R

更新日期：2003-12-01 00:00:00

abstract：:Ventricular remodeling is a compensatory response that comprises the processes of apoptosis, muscle cell hypertrophy, and rearrangement of the extracellular matrix fibers connecting the muscles. These processes are associated with transformation of endothelium and/or fibroblasts to myofibroblasts. Neutral matrix metal...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tyagi SC,Hoit BD

更新日期：2002-10-01 00:00:00

abstract：BACKGROUND:Allogeneic cardiosphere-derived cells (CDCs) exert cardioprotective effects when administered intracoronarily after reperfusion in animal models of acute myocardial infarction (AMI). The "no-reflow" phenomenon develops rapidly post-reperfusion and may undermine the efficacy of cell therapy, due to poor cell ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sousonis V,Sfakianaki T,Ntalianis A,Nanas I,Kontogiannis C,Aravantinos D,Kapelios C,Katsaros L,Nana M,Sampaziotis D,Sanoudou D,Papalois A,Malliaras K

更新日期：2021-01-01 00:00:00

abstract：:Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist remains a mainstay in the prevention of ischemic events following coronary stent placement. Significant controversy exists regarding the optimal management of high platelet reactivity despite antiplatelet therapy; however this finding has been cons...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Weeks PA,Sieg A,Paruthi C,Rajapreyar I

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a speci...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Zhou M,Ma C,Liu W,Liu H,Wang N,Kang Q,Li P

更新日期：2015-09-01 00:00:00

abstract：:Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gallego P,Roldán V,Lip GY

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

更新日期：2013-09-01 00:00:00

abstract：:Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of car...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Salinas G,Rangasetty UC,Uretsky BF,Birnbaum Y

更新日期：2007-06-01 00:00:00

abstract：:In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LD...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gomes FLT,Maranhão RC,Tavares ER,Carvalho PO,Higuchi ML,Mattos FR,Pitta FG,Hatab SA,Kalil-Filho R,Serrano CV Jr

更新日期：2018-11-01 00:00:00

abstract：:Cardiovascular diseases are one of the most common causes of death in humans and are responsible for billions of dollars in health care expenditures. As the molecular basis of cardiac diseases continues to be explored, there remains the hope for identification of more effective therapeutics. MicroRNAs (miRNAs) are rec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Calway T,Kim GH

更新日期：2015-03-01 00:00:00

abstract：:Acute medical illnesses are associated with a prolonged elevation in inflammatory markers that predisposes patients to thrombosis beyond the duration of their hospital stay. In parallel, both observational and randomized data have demonstrated a rate of postdischarge venous thromboembolic events that often exceeds tha...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Korjian S,Daaboul Y,Halaby R,Goldhaber SZ,Cohen AT,Singh K,Susheela AT,Harrington RA,Hull RD,Hernandez AF,Gibson CM

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. DESIGN:The present study was performed to evaluate whether combination therapy of cl...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Niu Q,Wang Z,Zhang Y,Wang J,Zhang P,Wang C,Yin X,Hou Y

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Intimal hyperplasia following percutaneous interventional vascular procedures is a major cause of restenosis. Although heparin inhibits intimal hyperplasia, it has not proven clinically useful in part due to an inadequate duration of intramural drug residence. This study was designed to evaluate the efficacy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sasseen BM,Gray BD,Gal D,Lorinc R,Carpenter DC,Klugherz BD,Wilensky RL

更新日期：2001-10-01 00:00:00

abstract：:Phosphodiesterase inhibitors as inodilators in heart failure are associated with promotion of arrhythmias. Calcium sensitizers have been proposed for the treatment of severe decompensated heart failure. The effect of levosimendan, a calcium sensitizer, and milrinone, a phosphodiesterase inhibitor, on ventricular arrhy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Papp JG,Pollesello P,Varró AF,Végh AS

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:Fluvastatin is an inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, effectively lowering serum cholesterol concentrations. A high-performance liquid chromatography (HPLC) assay was developed that determined the pharmacokinetics of fluvastatin in healthy individuals after administrat...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Siekmeier R,Lattke P,Mix C,Park JW,Jaross W

更新日期：2001-04-01 00:00:00

abstract：:BACKGROUND: Micropuncture studies were performed to determine the intrarenal hemodynamic effects of two conventional antihypertensive agents, hydrochlorothiazide (HCTZ) and hydralazine (HYDR) alone and in combination. METHODS AND RESULTS: Male spontaneously hypertensive and normotensive Wistar Kyoto rats (19 weeks old...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Komatsu K,Numabe A,Ono Y,Frohlich ED

更新日期：1996-01-01 00:00:00

abstract：BACKGROUND:Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor. Statins are reported to increase 25(OH)VitD concentration. Animal studies suggest that ezetimibe is a moderate inhibitor of intestinal 25(OH)VitD absorption, but its effect in humans i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Liberopoulos EN,Makariou SE,Moutzouri E,Kostapanos MS,Challa A,Elisaf M

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Brief periods of reocclusion (postconditioning) during early reperfusion reduce myocardial infarct size. Whether postconditioning has an effect on lethal ventricular arrhythmias independent of infarction in an in-vivo regional ischemia model is unknown. The purpose of this study was to determine if postcondi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kloner RA,Dow J,Bhandari A

更新日期：2006-03-01 00:00:00

abstract：:BACKGROUND: The tendency for the electrophysiologic effect of class III antiarrhythmic agents (action potential prolongation) to be diminished at faster heart rates represents a major drawback of this class of drug and is usually referred to as "reverse use dependence." A novel class III agent, MS-551, has recently be...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Nakaya Y,Martin DK,Campbell TJ

更新日期：1997-01-01 00:00:00

abstract：:Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomit...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ilebekk A,Eriksen M,Sevre K,Aspelin T,Björkman JA,Lyberg T,Nordlander M

更新日期：2006-09-01 00:00:00

abstract：BACKGROUND:In recent decades, clinical trials have played an increasingly important role in determining how we practice. Trial results proving that a clinical finding poses risk have led to interventions that try to reduce risk. Clinical trials proving that a particular therapy provides better outcome than another ther...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Reiffel JA

更新日期：2000-01-01 00:00:00

abstract：BACKGROUND:The well-described morning peak in the onset of acute coronary syndromes has been partly attributed to increased platelet activity upon arising. It has been suggested that stent thrombosis (ST) exhibits a similar pattern. We assessed whether a diurnal variation in ST occurs, and whether more robust antiplate...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Mogabgab O,Wiviott SD,Cannon CP,Sloan S,Sabatine MS,Antman EM,Braunwald E,Giugliano RP

更新日期：2013-11-01 00:00:00

abstract：:Vascular smooth muscle tone plays a fundamental role in regulating blood pressure, blood flow, microcirculation, and other cardiovascular functions. The cellular and molecular mechanisms by which vascular smooth muscle contractility is regulated are not completely elucidated. Recent studies show that the actin cytoske...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tang DD,Anfinogenova Y

更新日期：2008-06-01 00:00:00

abstract：:Postischemic accumulation of intracellular Na+ promotes calcium overload and contributes to cellular necrosis. Cardioprotection afforded by pharmacologic blockade of the sodium-hydrogen exchanger subtype 1 (NHE1) is thought to be more remarkable than that obtained by ischemic conditioning (IC). The window of protectio...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kingma JG

更新日期：2018-05-01 00:00:00